Valuation: MiMedx Group, Inc.

Market Cap 695M 611M 576M 526M 983M 66.71B 992M 6.89B 2.67B 33.98B 2.61B 2.55B 110B P/E 2026 *
-27.7x
P/E 2027 * 64.2x
Enterprise Value 695M 611M 576M 526M 983M 66.71B 992M 6.89B 2.67B 33.98B 2.61B 2.55B 110B EV / Sales 2026 *
2.58x
EV / Sales 2027 * 2.12x
Free-Float
95.59%
Yield 2026 *
-
Yield 2027 * -
1 day-1.26%
1 week-0.42%
Current month+3.74%
1 month+8.78%
3 months+26.27%
6 months+11.08%
Current year-30.43%
1 week 4.61
Extreme 4.614
4.99
1 month 4.27
Extreme 4.27
4.99
Current year 3.02
Extreme 3.025
6.79
1 year 3.02
Extreme 3.025
7.97
3 years 3.02
Extreme 3.025
10.14
5 years 2.43
Extreme 2.43
10.14
10 years 0.95
Extreme 0.95
18.25
Manager TitleAgeSince
Chief Executive Officer 63 2023-01-26
Director of Finance/CFO 60 2023-07-04
Chief Tech/Sci/R&D Officer - 2021-05-31
Director TitleAgeSince
Director/Board Member 73 2019-06-18
Chairman 73 2019-06-18
Director/Board Member 63 2019-06-18
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/26 Tax

Chief Financial Officer

-12,749 0.0086%
3/13/26 Tax

Executive/Senior Manager

6,762 0.0046%
3/13/26 Tax

Chief Administrative Officer

20,245 0.0136%
Change 5-day change 1-year change 3-year change Capi.($)
-1.26%-0.42%-33.76%-37.86% 695M
+0.53%-14.03% - - 1.18B
+0.18%+1.08%+58.49% - 357M
+0.59%+8.22%-40.54%-23.60% 127M
-1.60%-6.12%-16.74%+15.72% 71.91M
Average -0.31%-0.39%-8.14%-15.25% 486.81M
Weighted average by Cap. -0.09%-2.43%-7.14%-31.53%

Financials

2026 *2027 *
Net sales 270M 237M 223M 204M 382M 25.89B 385M 2.67B 1.04B 13.19B 1.01B 991M 42.84B 329M 289M 272M 249M 465M 31.53B 469M 3.26B 1.26B 16.06B 1.23B 1.21B 52.18B
Net income -25.45M -22.37M -21.07M -19.26M -35.99M -2.44B -36.29M -252M -97.85M -1.24B -95.55M -93.47M -4.04B 11.23M 9.87M 9.3M 8.5M 15.88M 1.08B 16.02M 111M 43.19M 549M 42.18M 41.26M 1.78B
Net Debt - -
Logo MiMedx Group, Inc.
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Employees
808
Date Price Change Volume
26-09-24 US$4.710 -1.26% 1,021,699
26-09-23 US$4.770 -3.25% 1,003,284
26-09-22 US$4.930 +2.49% 1,032,049
26-09-21 US$4.810 +0.84% 915,909
26-09-18 US$4.770 +1.71% 3,904,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.770USD
Average target price
7.400USD
Spread / Average Target
+55.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDXG Stock